RxDoctor Payments Data

Emily Didio

Family · Chesapeake, VANPI 1073226668

Payments from drug & device makers

$932in general payments, 2019–2025

Across 17 payments — averaging $54.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$246
  • Inspire Medical Systems, Inc.$220
  • AstraZeneca$211
  • Sanofi$161
  • Regeneron Healthcare Solutions, Inc.$47
  • Philips North America LLC$26
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$932100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$932 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$28,146
Medicare patients
266
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter336$299,679
Breztri AerosphereBudesonide/Glycopyr/Formoterol89$84,152
Breo ElliptaFluticasone/Vilanterol97$46,538
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$25,278
Spiriva RespimatTiotropium Bromide22$23,192
Fluticasone-SalmeterolFluticasone Propion/Salmeterol51$14,100
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$12,986
EliquisApixaban12$10,985
Wixela InhubFluticasone Propion/Salmeterol44$7,919
Albuterol Sulfate HfaAlbuterol Sulfate323$7,646
SymbicortBudesonide/Formoterol Fumarate22$7,311
Advair HfaFluticasone Propion/Salmeterol11$6,355
Theophylline ErTheophylline Anhydrous28$3,278
Montelukast Sodium407$2,874
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$246$371,494473 claims
AstraZenecaBreztri Aerosphere, Symbicort$211$91,462111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →